鼠曲草提取物与苯溴马隆有益相互作用:大鼠药代与药效研究
在大鼠中研究鼠曲草提取物(GAD)与苯溴马隆(BBR)联用的药代和药效相互作用。正常大鼠重复给予GAD使BBR的AUC和MRT显著增加(p<0.05);高尿酸血症肾病大鼠中GAD后给药提高BBR生物利用度和肠肝循环,降尿酸最大效应为84.3%(急性)、71.4%(7天)和82.5%(14天)。GAD抑制CYP2C11(9)介导的甲苯磺丁脲代谢,AUC增加≥1.25但<2倍。
要点
- GAD重复给药可显著增加BBR的AUC并延长MRT(p<0.05)。
- HN大鼠中GAD后给药提高BBR生物利用度与肠肝循环,降尿酸效应增强。
- GAD抑制CYP2C11(9)介导代谢,AUCtolbutamide增加≥1.25但<2倍。
核心结论
- BBR+GAD联用的药效协同部分可由CYP2C11(9)介导和肠肝循环的药代相互作用解释。
研究设计与样本
- 正常大鼠单次灌胃BBR(4.5或50 mg/kg)或联用单次/多次GAD(450 mg/kg)进行药代研究。
- 雄性HN大鼠多次灌胃BBR(4.5 mg/kg/day)或联用多次GAD(450 mg/kg/day)进行药代和药效研究。
- 采用体内cocktail法测定GAD对CYP2C11(9)和1A2介导药物代谢的影响。
主要发现
- 正常大鼠重复给予GAD使BBR的AUC显著增加并延长MRT(p<0.05)。
- 雌性大鼠BBR及代谢产物羟基苯溴马隆的系统暴露显著高于雄性(p<0.05)。
- HN大鼠中GAD后给药使BBR生物利用度和肠肝循环显著提高,T1/2和MRT延长(p<0.05)。
- BBR+GAD降尿酸效应在多数时间点显著高于BBR单用,最大效应为84.3%(急性)、71.4%(7天)和82.5%(14天)。
- GAD对CYP2C11(9)介导的甲苯磺丁脲代谢有显著抑制作用,AUCtolbutamide增加≥1.25但<2倍。
关键数值与推荐
- 正常大鼠BBR剂量为4.5或50 mg/kg,GAD剂量为450 mg/kg(单次或每日一次×7天)。
- HN大鼠BBR剂量为4.5 mg/kg/day,GAD剂量为450 mg/kg/day(BBR给药后2小时)。
- 降尿酸最大效应:急性84.3%、7天亚慢性71.4%、14天亚慢性82.5%。
- AUCtolbutamide增加≥1.25但<2倍提示CYP2C11(9)抑制。
临床怎么用
- 临床联用BBR与GAD时需关注BBR暴露增加及降尿酸效应增强的可能。
- 雌雄大鼠暴露差异提示性别可能影响BBR的药代特征。
- GAD对CYP2C11(9)的抑制提示需评估经该酶代谢药物的相互作用风险。
局限性
- 研究仅在大鼠中进行,结论外推至人体需谨慎。
- 样本量、P值等具体统计信息未在摘要中完整报告。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Gnaphalium affine D. Don extract (GAD) enhanced efficacy and reduced toxicity of benzbromarone (BBR) in combination use. However, little is known about effects of GAD on the pharmacokinetics (PKs) and metabolic enzymes of BBR. PURPOSE: To investigate the pharmacokinetic (PK) and pharmacodynamic (PD) mechanism of the herb-drug interactions (HDIs) between GAD and BBR. STUDY DESIGN AND METHODS: Intragastric single BBR (4.5 or 50 mg/kg), single BBR (4.5 or 50 mg/kg) + single GAD (450 mg/kg, 2 h after BBR-administration), or single BBR (4.5 or 50 mg/kg) + multiple GAD (450 mg/kg/day, once daily for 7 days) were administered to both sexes for BBR PK studies in normal rats. Intragastric multiple BBR (4.5 mg/kg/day), or multiple BBR (4.5 mg/kg/day) + multiple GAD (450 mg/kg/day, 2 h after BBR-administration) were administered for BBR PK and PD studies in male rats with hyperuricemic nephropathy (HN). The cumulative anti-hyperuricemic effects of BBR and BBR+GAD were determined by plasma uric acid (UA) concentration-time curve and area under curve (AUCUA). An in vivo cocktail approach was employed to determine the effects of GAD on cytochrome P450 (CYP) 2C11(9) and 1A2 - mediated drug metabolism. RESULTS: In normal rats, the repeated dose administration of GAD induced a significant increase of BBR AUC and prolonged the mean residence time (MRT) (p < 0.05). systemic exposure to BBR and metabolically derived hydroxybenzbromarones was significantly greater in female compared with male rats (p < 0.05). In HN rats, post-administration of GAD resulted in significantly higher bioavailability and enterohepatic recycling (ER) of BBR relative to the BBR alone administrated group from the prolongation of terminal elimination half-life (T1/2) and MRT of BBR (p < 0.05). Significantly higher urate-lowering effect of BBR+GAD compared with BBR alone was generally observed at post-dosing most time points with a maximal effect of 84.3% (acute treatment), 71.4% (7-day subchronic treatment) and 82.5% (14-day subchronic treatment) reduction in UA levels. Additionally, GAD showed a significant inhibitory effect on CYP2C11(9)-mediated tolbutamide (probe substrate) metabolism with ≥ 1.25 but < 2-fold increase in AUCtolbutamide. CONCLUSIONS: PD synergism demonstrated with the BBR+GAD combination could be explained by the PK interaction observed partially from CYP2C11(9)-mediation and enterohepatic recycling.
引用
- Liu X, Han S, Yang Q, et al. Beneficial herb-drug interaction of Gnaphalium affine extract on benzbromarone: A pharmacokinetic and pharmacodynamic study in rats. Phytomedicine. 2022. PMID: 35660349. doi:10.1016/j.phymed.2022.154203
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。